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Background: The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined
beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients
with refractory pancreatic cancer.
Materials and methods: A retrospective review was carried out in patients with pancreatic
adenocarcinoma at Siteman Cancer Center, who had received nab-paclitaxel monotherapy after experiencing
disease progression on standard treatments. Nab-paclitaxel was given either two out of every three weeks or
three out of every four weeks.
Results: Twenty patients were identified and included for data analysis. Median age was 63.5 years old. All
patients had previously received gemcitabine, while 40% had also received FOLFIRINOX. Median number
of prior lines of systemic treatment was 2. Patients were treated for a median of 15 weeks, with a range of
1 to 41.7 weeks. Median dose of nab-paclitaxel was 100 mg/m2 with range of 75-125 mg/m2. Best response
imaging was available in 17 patients and 11 out of the 17 patients (64.7%) had stable disease. Median
progression-free survival (PFS) was 3.7 months and overall survival (OS) were 5.2 months. Most common
treatment related toxicities included grade 1 pneumonitis in five patients (25%), grade 3 or 4 neutropenia in
three patients (15%), and dehydration resulting in hospitalization in one patient (5%).
Conclusions: Nab-paclitaxel monotherapy had acceptable level of toxicity in a heavily pretreated patient
population with pancreatic cancer and appeared to provide a clinical benefit. This agent is worthy of further
prospective studies to evaluate extent of benefit after standard therapies have failed.
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Background
Pancreatic adenocarcinoma remains a notoriously lethal
malignancy, currently ranking as the fourth leading cause
of cancer related death in the US, despite a relatively low
incidence (1). Until recently, gemcitabine and erlotinib
were the only agents known to improve overall survival
(OS) in patients with unresectable pancreatic cancer
to approximately 6 to 7 months (2). In 2011, a nongemcitabine based therapy, FOLFIRINOX, was shown
to improve survival to 11 months when compared with
gemcitabine in a phase III randomized clinical trial in
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the first line setting (3). After failure of first line therapy,
however, the options continue to be even more limited.
There are currently no widely accepted treatments beyond
first line. The only regimen to show evidence of survival
benefit in a context of a randomized trial in this setting is
oxaliplatin/5-FU/leucovorin (OFF), which improved overall
survival to 4.8 months from 2.3 months with best supportive
care (4).
Nab-paclitaxel (trade name, Abraxane), is paclitaxel
bound to nano-particle albumin, a first drug of this
type. Nab-paclitaxel was initially developed to avoid
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hypersensitivity reactions that resulted from solvents
such as cremephor that are used to dissolve paclitaxel.
Nab-paclitaxel has been approved by the Food and Drug
Administration since 2004 for use in metastatic breast
cancer as well as metastatic non-small cell lung cancer
(5,6). In addition to eliminating hypersensitivity reaction,
it has also been postulated that uptake of albumin by tumor
cells may allow improved intra-tumoral delivery of nabpaclitaxel. This may be especially relevant in pancreatic
cancer given the dense stromal component of this
malignancy that has been postulated as being central to its
chemoresistance (7). In fact, a protein present in stroma
of many pancreatic adenocarcinomas, secreted protein
acidic and rich in cysteine (SPARC), may help serve as an
albumin-binding protein that sequesters nab-paclitaxel to
concentrate the drug intratumorally (8).
Nab-paclitaxel was first used in pancreatic cancer
two years ago in combination with gemcitabine in the setting
of a phase I-II study, where it was found to be tolerable
with substantial activity (9). The results of a phase III trial
comparing gemcitabine to gemcitabine combined with nabpaclitaxel were recently presented in abstract form showing
improved survival of two months from 6.7 to 8.5 months
with the combination therapy in previously untreated
patients with advanced pancreatic cancer (10). In the second
line setting, a small phase II study has also shown evidence
of activity of nab-paclitaxel monotherapy in patients who
have progressed through gemcitabine (11). This study
involved 19 patients and showed an overall survival of
7.3 months. 36.8% of patients had stable or partial response
on best imaging in this study. No other data is available,
to the best of our knowledge, however, on the use of nabpaclitaxel monotherapy in refractory pancreatic cancer,
which is an area of dire need. Here, we report the results of
a retrospective and prospective registry study documenting
our experience with nab-paclitaxel monotherapy in heavily
pretreated pancreatic cancer patients.
Materials and methods
Patient population
Patients with pancreatic adenocarcinoma at Washington
University in St. Louis Siteman Cancer Center, who
were treated with nab-paclitaxel monotherapy between
January 2009 and July 2012, were eligible for inclusion.
A retrospective and prospective registry was established
to capture all patients after Institutional Board Review
(IRB) approval was obtained. Patients were 18 years of
age or older and had pathologically confirmed pancreatic
adenocarcinoma. All patients had advanced or recurrent
pancreatic cancer which had progressed through at least one
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earlier line of chemotherapy. Demographic data collected
included age, race, gender, ECOG performance status, and
prior treatments. Baseline laboratory values were recorded
including tumor marker CA 19-9. Data collection was
stopped in September 2012. All patients treated with at least
one dose of nab-paclitaxel were included for analysis.
Treatment and monitoring
Nab-paclitaxel dosing and schedule (every week for
two weeks then one week off versus every week for
three weeks then one week off) was chosen by the practicing
oncologist. The dose and schedule used was recorded for
the purposes of this study. Staging imaging (CT or MRI)
was obtained per the discretion of the treating oncologists
during treatment. When available after at least one month
of therapy, the images were analyzed according to the
Response Evaluation Criteria in Solid Tumors. Clinic notes
were also reviewed for clinician assessment of response
and if it differed from radiological assessment, the clinical
assessment of response was to be used.
All clinic notes were reviewed for any hospitalizations,
dose reductions or cessation of treatment due to adverse
events. Laboratory values before and after each treatment
cycle were also reviewed to corroborate and document any
additional adverse events using complete blood count and
comprehensive metabolic panel in each patient. Adverse
events were graded using National Cancer Institute
Common Terminology Criteria for Adverse Events
(version 4.0). Patients who received at least one dose of
chemotherapy were included for toxicity evaluation.
Statistical analysis
Data analysis for this study was descriptive in nature.
Demographic and clinical characteristics, as well as
adverse events and follow-up time were summarized using
means, medians, counts and frequencies as appropriate.
Progression-free survival (PFS) was defined as time of
nab-paclitaxel initiation to time of progression based on
imaging/clinical evaluation, or time of death, whichever
occurred first. Those patients alive and progression-free
were censored on September 1, 2012. OS was defined as
time of nab-paclitaxel initiation to time of death. When not
noted in clinical records, the Social Security Death index
was used to ascertain survival
Results
Patients
A total of 20 patients were registered for this study. Four
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Table 2 Best response by RECIST criteria in 17 patients with

Table 1 Baseline patient characteristics

available imaging after at least one month of therapy

Patient characteristics
Total number of patients

20

Age-yr
Median
Range

Response

63.5

Partial or complete response

45-84

Stable disease

Number of patients with response/
evaluable number of patients (%)
0/17
11/17 (64.7%)

Disease progression

6/17 (35.3%)

10 (50%)

50% decline in CA 19-9

7/12 (58.3%)

Female

10 (50%)

Last row shows number/percentage of patients with a baseline

ECOG 0-1

18 (90%)

elevated CA 19-9 level, who had a 50% or more decline in CA

Gender
Male

Previous chemotherapy
Gemcitabine

20 (100%)

FOLFIRINOX

8 (40%)

Nab-Paclitaxel combination regimens

3 (15%)

of the 20 had already finished treatment at the start of this
registry and were reviewed retrospectively. The rest were
reviewed either completely prospectively or prospectively
and retrospectively as appropriate (5 and 11 patients
respectively). Patient characteristics are listed in Table 1.
Median age of patients was 63.5, with a wide range of 45 to
84 years old. There were equal number of men and women
and majority had an ECOG of 0 or 1 (90%). All patients
had previously received gemcitabine monotherapy and some
had progressed through other additional chemotherapies,
including FOLFIRINOX in 8 patients and nab-paclitaxel
combined with other agents in 3 patients. Median
number of prior lines of therapy was 2, with a range of
1 to 4. Overall, 18 patients (90%) had received at least two
prior treatment regimens.
Treatment
Patients received treatment for a median of 15 weeks, ranging
from one to six cycles. Eleven patients (55%) were able to
receive therapy for at least 4 months. Patients were started
on nab-paclitaxel at 100 or 125 mg/m2, with three patients
having doses later decreased to 75 or 80 mg/m2. Roughly
half the patients were treated on a three week on, one week
off cycle, while the other half were treated on a two week on,
one week off cycle. Median dose was 100 mg/m2.
Majority of patients discontinued treatment due to
either progression of disease or decline in functional status
(15 patients, 75%). Three patients (15%) were still on nabpaclitaxel at the time of closing study data collection.
Clinical outcome
Best response imaging was available in 17 patients (Table 2).
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19-9 levels after therapy

Of these patients, while no patient had a complete or partial
response, 65% had stable disease at as their best response
on imaging. 35% progressed without any stabilization of
disease. There was no discrepancy between response by
imaging and clinical impression. Of the 12 patients who had
elevated baseline CA 19-9, seven (58%), had a 50% or more
decline in levels. The three patients who had uninterrupted
CA 19-9 elevation post therapy were all shown to have
progressive disease on first imaging.
Median progression free survival was 3.7 months. In
patients who had a response, median duration of response
was 4.7 months. At the end of data collection, 6 out of
19 patients were still living. Median overall survival in the
study population was 5.2 months.
Adverse events
Adverse events directly attributed to nab-paclitaxel were
the cause of treatment discontinuation in only two patients
(10%), both being mucositis, in one concurrently with
neutropenia. Grade 2 or worse fatigue was seen in four
patients while significant dehydration was seen in one
patient (grade 3). Only one patient was hospitalized as a
result of therapy. Three patients (15%) developed grade
3 or 4 neutropenia with one also developing neutropenic
fever. An unexpected adverse event possibly related to nabpaclitaxel was pneumonitis that occurred in five patients. All
cases of pneumonitis were grade 1.
Discussion
Advanced pancreatic cancer has recently witnessed the
introduction of the first regimens to improve on gemcitabine
therapy in decades. Two years ago, FOLFIRINOX, a
combination regimen consisting of 5-FU, oxaliplatin and
irinotecan was shown in a landmark study to improve survival
compared with gemcitabine from 6.8 to 11.1 months (3).
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Earlier this year, combination of gemcitabine with nabpaclitaxel was also shown to improve survival compared with
gemcitabine, albeit more modestly from 6.7 to 8.5 months (10).
Although these developments are cause for hope in a field
which has seen little to be excited about in a long time,
they clearly represent modest progress. Patients eventually
progress through these regimens and there is a dire need for
treatment options beyond first line of therapy.
Here we present a registry study examining nabpaclitaxel monotherapy beyond first line of therapy. 90%
of patients included in our study had received at least
two other lines of therapy, including nab-paclitaxel
combination therapy and/or FOLFIRINOX in some. We
found nab-paclitaxel therapy to be relatively well tolerated
in this pretreated patient population with good level of
clinical activity. The PFS was 3.7 months and OS was
5.2 months, with more than 4 months duration of response
in patients who had stabilization of disease. Responses in
CA 19-9 were seen along with imaging response.
Our study has the usual limitations of being a non
randomized study. Nab-paclitaxel dosage schedule and dose
reductions in response to toxicity were at the discretion of
the treating oncologist thereby limiting recommendations
on a dose schedule. Despite these limitations and the small
number of patients, however, our results are consistent with
evidence of benefit from nab-paclitaxel monotherapy seen
in another small study (11). Furthermore, our study is the
first to our knowledge to include patients treated with either
nab-paclitaxel combination therapy or FOLFIRINOX.
This is significant given that either of these two regimens
is now considered a standard treatment option for first line
therapy of patients with advanced pancreatic cancer. Our
study represents evidence that nab-paclitaxel monotherapy
could be an option in these patients upon progression.
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